Iperion (NZSE:IPR) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Iperion SpecialCharges?

Special Charges only applies to banks.

Iperion Business Description

Address c/o Duncan Cotterill, 50 Customhouse Quay, Level 2 Tower Building, Wellington, NTL, NZL, 6011
Iperion Ltd is a New Zealand-based biotechnology company focused on the development and commercialisation of antimicrobial technologies. Its principal product is Pathoglaze, an antimicrobial coating designed to reduce microbial contamination on surfaces in healthcare, food processing, and other hygiene-sensitive environments. The company's revenue model centres on licensing its proprietary technology and selling coating products to commercial and institutional customers, primarily within New Zealand. Iperion operates as a single geographic segment and has historically been an early-stage venture, with activities centred on product development, regulatory validation, and establishing commercial partnerships to bring its antimicrobial coatings to market. Its customers include organisations seeking to improve infection control and surface hygiene. The company remains closely tied to the New Zealand innovation and life sciences sector.